Literature DB >> 23459187

Immunological faecal occult blood testing: a discriminatory test to identify colorectal cancer in symptomatic patients.

A Kaul1, A Shah, F H Magill, S A Hawkins, P Skaife.   

Abstract

INTRODUCTION: Current investigation for patients with colorectal symptoms without overt rectal bleeding is undertaken by colonoscopy or by flexible sigmoidoscopy and barium enema. A large majority of patients do not have colorectal cancer. There exists no instant, objective measure to discriminate patients who are likely to have colorectal cancer and therefore require expedient investigation. AIM: To evaluate the sensitivity and specificity of immunological faecal occult blood testing (FOBT) in patients with colorectal symptoms without overt rectal bleeding.
METHODS: Consecutive patients referred for urgent colonic investigation, were prospectively studied. A faecal sample was obtained from each one and subjected to immunological FOB which tested either negative or positive. All patients then underwent complete colonic imaging. The correlation between FOBT status and results from colonic imaging was studied.
RESULTS: Of 126 tested, thirty patients (26.8%) were FOBT positive. One hundred and twelve patients underwent complete colonic imaging. In the FOBT positive group colonic imaging identified 17 cases of histologically proven adenocarcinoma, 1 recurrent squamous cell carcinoma of anus, 1 adenomatous polyp, 6 cases of diverticulosis, and no pathology in 5 cases. In the 82 FOBT negative patients, no cancers were found. Overall the Immunological Faecal Occult Blood Test was found to have 100% sensitivity and 86.3% specificity.
CONCLUSION: Immunological faecal occult blood testing is a sensitive and specific test in identifying colorectal cancer and may be useful in identifying those patients who warrant urgent investigation. Routine clinical application may be useful in the allocation of resources. Crown
Copyright © 2013. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23459187     DOI: 10.1016/j.ijsu.2013.02.013

Source DB:  PubMed          Journal:  Int J Surg        ISSN: 1743-9159            Impact factor:   6.071


  7 in total

Review 1.  Home-use faecal immunochemical testing: primary care diagnostic technology update.

Authors:  Brian D Nicholson; Matthew Thompson; Christopher P Price; Carl Heneghan; Annette Plüddemann
Journal:  Br J Gen Pract       Date:  2015-03       Impact factor: 5.386

Review 2.  Role of Raman spectroscopy and surface enhanced Raman spectroscopy in colorectal cancer.

Authors:  Cerys A Jenkins; Paul D Lewis; Peter R Dunstan; Dean A Harris
Journal:  World J Gastrointest Oncol       Date:  2016-05-15

3.  Implementation of immunochemical faecal occult blood test in general practice: a study protocol using a cluster-randomised stepped-wedge design.

Authors:  Jakob Søgaard Juul; Flemming Bro; Nete Hornung; Berit Sanne Andersen; Søren Laurberg; Frede Olesen; Peter Vedsted
Journal:  BMC Cancer       Date:  2016-07-11       Impact factor: 4.430

4.  Faecal haemoglobin and faecal calprotectin as indicators of bowel disease in patients presenting to primary care with bowel symptoms.

Authors:  Craig Mowat; Jayne Digby; Judith A Strachan; Robyn Wilson; Francis A Carey; Callum G Fraser; Robert J C Steele
Journal:  Gut       Date:  2015-08-20       Impact factor: 23.059

Review 5.  Diagnostic Accuracy Of Fecal Occult Blood Tests For Detecting Proximal Versus Distal Colorectal Neoplasia: A Systematic Review And Meta-Analysis.

Authors:  Ming Lu; Xiaohu Luo; Ni Li; Hongda Chen; Min Dai
Journal:  Clin Epidemiol       Date:  2019-10-25       Impact factor: 4.790

6.  Stage-Specific Sensitivity of Fecal Immunochemical Tests for Detecting Colorectal Cancer: Systematic Review and Meta-Analysis.

Authors:  Tobias Niedermaier; Yesilda Balavarca; Hermann Brenner
Journal:  Am J Gastroenterol       Date:  2020-01       Impact factor: 12.045

7.  Could it be colorectal cancer? General practitioners' use of the faecal occult blood test and decision making--a qualitative study.

Authors:  Cecilia Högberg; Eva Samuelsson; Mikael Lilja; Eva Fhärm
Journal:  BMC Fam Pract       Date:  2015-10-26       Impact factor: 2.497

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.